Your browser doesn't support javascript.
loading
Mechanisms that determine nanocarrier targeting to healthy versus inflamed lung regions.
Brenner, Jacob S; Bhamidipati, Kartik; Glassman, Patrick M; Ramakrishnan, N; Jiang, Depeng; Paris, Andrew J; Myerson, Jacob W; Pan, Daniel C; Shuvaev, Vladimir V; Villa, Carlos H; Hood, Elizabeth D; Kiseleva, Raisa; Greineder, Colin F; Radhakrishnan, Ravi; Muzykantov, Vladimir R.
Afiliação
  • Brenner JS; Pulmonary and Critical Care Division, University of Pennsylvania, Philadelphia, PA, USA; Department of Pharmacology and Center for Translational Targeted Therapeutics and Nanomedicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Bhamidipati K; Department of Pharmacology and Center for Translational Targeted Therapeutics and Nanomedicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Glassman PM; Department of Pharmacology and Center for Translational Targeted Therapeutics and Nanomedicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Ramakrishnan N; Department of Bioengineering, University of Pennsylvania, Philadelphia, PA, USA.
  • Jiang D; Department of Respiratory Medicine, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.
  • Paris AJ; Pulmonary and Critical Care Division, University of Pennsylvania, Philadelphia, PA, USA.
  • Myerson JW; Department of Pharmacology and Center for Translational Targeted Therapeutics and Nanomedicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Pan DC; Department of Pharmacology and Center for Translational Targeted Therapeutics and Nanomedicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Shuvaev VV; Department of Pharmacology and Center for Translational Targeted Therapeutics and Nanomedicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Villa CH; Department of Pharmacology and Center for Translational Targeted Therapeutics and Nanomedicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Hood ED; Department of Pharmacology and Center for Translational Targeted Therapeutics and Nanomedicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Kiseleva R; Department of Pharmacology and Center for Translational Targeted Therapeutics and Nanomedicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Greineder CF; Department of Pharmacology and Center for Translational Targeted Therapeutics and Nanomedicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Radhakrishnan R; Department of Bioengineering, University of Pennsylvania, Philadelphia, PA, USA.
  • Muzykantov VR; Department of Pharmacology and Center for Translational Targeted Therapeutics and Nanomedicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: muzykant@mail.med.upenn.edu.
Nanomedicine ; 13(4): 1495-1506, 2017 05.
Article em En | MEDLINE | ID: mdl-28065731
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Portadores de Fármacos / Nanopartículas / Inflamação / Pulmão / Epitopos Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: Nanomedicine Assunto da revista: BIOTECNOLOGIA Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Portadores de Fármacos / Nanopartículas / Inflamação / Pulmão / Epitopos Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: Nanomedicine Assunto da revista: BIOTECNOLOGIA Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Estados Unidos